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Vital dye is enough for inguinal sentinel lymph node biopsy in
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ABSTRACT
Purpose: The importance of gamma probe detection (GPD) combined with vital dye for sentinel node (SN) biopsy is well
accepted. We evaluated the efficacy of patent blue dye (PBD) in identifying inguinal SN. Methods: Ninety-four cutaneous
melanoma patients with inferior extremity lesions were submitted to SNB according to a established protocol. Patients
were randomized in two groups: Blue group, where SN was identified by PPD and Probe group, where SN was identified by
GPD. The median age was 44.2 years and median Breslow thickness was 2.1 mm. Preoperative lymphoscintigraphy,
lymphatic mapping with PBD and intra-operative GPD was performed on all patients. Histological examination of SN
consisted of hematoxylin-eosin and immunohistochemical staining. If micrometastases were present complete
lymphadenectomy was performed. The SN was considered as identified by PBD if it was blue and identified by GPD if it
demonstrated at least ten times greater radioactivity than background. Results: It was explored 94 inguinal lymphatic
basins, 145 SN were excised (70 guided primarily by blue dye and 75 guided primarily by probe). All SN identified by
preoperative lymphoscintigraphy were excised. In the Blue group PPD identified all SN and all of them were hot. In the
Probe group all SN were identified by probe and were blue. The coincidence of PPD and GPD was 100%. Conclusion:
Patent blue dye is enough to identify superficial inguinal SN in cutaneous melanoma.
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RESUMO
Objetivo: a importância da detecção gama intra-operatória combinada com corante vital para biópsia de linfonodo sentinela
é bem aceita. Nós avaliamos a eficácia do azul patente V na identificação do linfonodo sentinela inguinal.
Métodos: Noventa e quatro pacientes portadores de melanoma cutâneo de membro inferior foram submetidos a biópsia de
linfonodo sentinela de acordo com protocolo estabelecido. Foram randomizados em dois grupos: Grupo Azul, onde o
linfonodo sentinela foi identificado primariamente com o corante vital azul patente V (Guerbet) e o Grupo Sonda, onde o
linfonodo sentinela foi identificado primariamente pela sonda de detecção gama (Neoprobe).  A idade mediana foi de 44,2
anos e a espessura mediana de  Breslow foi 2,1 mm. Linfocintilografia pré-operatória, mapeamento linfático com azul
patente V e detecção gama intra-opertaória foram realizados em todos os pacientes. O exame histopatológico do linfonodo
sentinela consistiu de hematoxilina-eosina e imunohistoquímica. Se micrometástase estivesse presente, linfadenectomia
completa era realizada. O linfonodo sentinela era considerado como identificado pelo corante vital se estivesse azul e
identificado pela sonda de detecção gama se demonstrasse pelo menos 10 vezes ou mais radioatividade do que o fundo.
Resultados: Foram exploradas 94 regiões inguinais, 145 linfonodos sentinelas foram excisados (70 dirigidos
primariamente pelo corante vital e 75 dirigidos pela sonda de detecção gama). Todos os linfonodos sentinelas
identificados pela linfocintilografia foram excisados. No grupo azul, todos os linfonodos sentinela foram primariamente
idenficados pelo corante vital e todos se apresentavam quentes na leitura pela sonda. No grupo sonda, todos os
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linfonodos sentinelas foram primariamente identificados pela sonda e estavam corados pelo azul. A coincidência da
sonda com o corante vital foi de 100%. Conclusão: Azul patente V foi suficiente para identificar linfonodo sentinela
inguinal em pacientes com melanoma cutâneo.
Descritores: Tintura. Vasos Linfáticos. Sonda. Linfonodos. Melanoma.
Introduction
Sentinel lymph node (SLN) biopsy has emerged by the
end of the 20th Century as a less aggressive procedure to
detect micrometastasis.1 Only patients with SLN metastasis
are submitted to complete lymphadenectomy. Patients
without metastasis are preserved, avoiding complications
as infection, sensibility disturbances and edema.2 This
technique has been considered in melanoma and breast
cancer staging since 2002 by AJCC / UICC.3,4 SLN procedure
involves three phases as follows: (1) preoperative
lymphoscintigraphy; (2) biopsy of the sentinel node – by
means of lymphatic mapping with vital dye and intra-
operative gamma probe detection (GPD); (3) histological
examination of the node.5 Lymphoscintigraphy shows the
drainage basins and allows localizing SLN and its projection
over the skin. It is essential for this procedure. Lymphatic
mapping with vital dye simulates the lymphatic way that
tumor cells could have followed from the primary lesion to
the SLN. The sentinel node becomes blue. Intra-operative
gamma probe detection permits an easy localization of SLN
and a less aggressive dissection.6,7 The importance of GPD
combined with vital dye for SLN biopsy is well accepted.8
From 1993 to 1996 we used only lymphatic mapping with
PPD for SNB. We observed that inguinal SN was always
found when preoperative lymphoscintigraphy showed
superficial inguinal SN. The costs of GPD are higher than
lymphatic mapping with vital dye. In our country several
cancer hospitals don’t have gamma probe detection device.
So, we proposed to evaluate the efficacy of patent blue dye
(PBD) in identifying alone superficial inguinal SN.
Methods
 Setting - Patients admitted at Oncology Prevention
Center – Sao Paulo and treated by a multidisciplinary team
(oncology surgeon, nuclear medicine physician and
pathologist), from January 1998 to October 2004.
 Patients - Among one hundred and ninety-two
melanoma patients submitted to SNB, 94 presented inguinal
SN only at preoperative lymphoscintigraphy and formed
our study group. All of them signed informed consent.
Melanoma primary site was inferior extremity and  Breslow
thickness was equal to or greater than 0.76 mm (average =
2.1mm; range: 0.76 – 7.0 mm). All patients were in vertical
growth phase. There were 44 men and 50 women.  The
average age was 44.2 years (range: 18 - 81 years old).
 Interventions - Patients were alternately allocated in
one of two groups: Blue group, where blue dye guided the
SNB and Probe group, where probe guided the SNB. If other
SN beyond the inguinal were detected on
lymphoscintigraphy, like popliteal or deep pelvic SN, the
patient were excluded. To perform preoperative
lymphoscintigrapy a quantity of 1 mCi (Tc99m - dextran 500)
in a 1 ml volume of 0.9% normal saline was injected
intradermally in equal parts into four quadrants around the
biopsy scar or the melanoma lesion if still present.
Immediately afterwards, dynamic images were obtained to
visualize the lymphatic drainage. Anterior and lateral static
images, using a dual-head gamma camera (Eucint Helix HR)
were obtained until the SLN was found. The last image was
obtained after 2 hours when whole body visualization was
done. These images were complemented by oblique views
whenever the injection site could obscure the SLN. The
position of the SLN was then marked on the skin. PBD was
performed in all patients according to the technique
described by Morton et al.9 Blue group - A 5 cm inguinal
incision was made over the SN skin point projection
determined by preoperative lymphoscintigraphy.
Subcutaneous tissue was dissected, identifying a blue-
stained lymphatic channel. The lymphatic channel was
carefully dissected down to the blue-stained SN (Figure 1).
FIGURE 1 - Inguinal sentinel node blue stained.
After excised, the radioactivity of the blue SN was
checked by probe.
 Probe group - A 3 cm incision was done over the
hottest point determined by intra-operative gamma probe
(Columbus, OH). The hottest node was excised and checked
if it was or not blue stained.  The operative field was checked
looking for another SLN (radioactivity more than 10% of
the hottest ex vivo SLN).
The specimen was sent for pathological examination,
using a paraffin hematoxylin-eosin section and
immunohistochemical staining (S-100 and HMB-45). Only
when micrometastases were present a formal regional
lymph node dissection was performed. The average
follow-up was 40 months.
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 Main measurement - The SN was considered as
identified by PBD if it was blue-stained and by GPD if it was
at least ten times more radioactive than background. No
special statistic methods were needed.
Results
PBD and GPD were used in all patients. In blue group
(47 patients), the inguinal SN was retrieved only by PPD, all
SN identified by preoperative lymphoscintigraphy were blue
(70 SN, 1.5 per lymphatic basin). When examined ex vivo by
probe, all the 70 SN were hot (at least 10 times more
radioactive than background). In probe group, the inguinal
SN was retrieved only by GPD, 75 SN were excised (1.6 per
lymphatic basin). All SN were blue stained. Micrometastasis
was found in 20 patients (21%), 16 on permanent sections
and 4 on immunohistochemistry only. Regional node
dissection was performed in 19 patients with micrometastatic
SN. In two patients were  found positive non sentinel node.
Four patients with a tumor - negative SN recurred: 2 recurred
in the same basin, 1 developed in-transit metastasis and the
other had liver metastasis. Median follow up of the 94
patients was 20 month. All of these recurrent patients had
Breslow thickness equal or more than 2.2 mm. Postoperative
complications after SLN were seen in six patients which
were solved easily (wound infection, hematoma and
seroma).
Discussion
The pathological status of SN is the most important
prognostic factor for melanoma recurrence. Sentinel node
procedure appears to be a reliable method for regional
microstaging of melanoma patients with clinically hidden
lymph node metastases.10,11 According our data,
micrometastasis was found in 21.0% (20/94 patients). Six
patients with negative SN recurred. Among 19 patients that
were submitted to complete lymph node dissection due to
positive SN, five (13,5%) had another positive node. Factors
that could predict the sentinel node status would be useful
for counseling patients about treatment options and
possible outcomes. Tumor thickness and ulceration of
primary lesion are considered dominant independent
predictors of sentinel node metastasis.12 Some authors have
been suggesting Breslow thickness, the amount of tumor
and interdigitating dendritic cells into the SN as prognostic
factors for non sentinel nodes status in melanoma patients.13
Literature has registered a lower identification rate when
using PPD alone than GPD for SNB (85%).14 When both
PBD and GPD procedures are combined success rate in
localizing SN is optimized (99-100%).15 In our study, PPD
identified all inguinal sentinel node when used alone and
all inguinal sentinel node was hot. By the other hand, in
GPD group, all inguinal sentinel node were identified by
probe and were blue stained. So, blue dye showed to be
enough for identifying superficial inguinal SN in inferior
extremity melanoma patients. Otherwise, probe facilitated
the procedure allowing a smaller incision. Previous study
had suggested similar results.16 Lymphoscintigraphy has a
crucial role in localizing the SN basin and allowing skin
localization of the SN. In case of inguinal sentinel node,
deep pelvic and popliteal SN has to be checked by
lymphoscintigraphy. It is known that learning curve for SNB
using lymphatic mapping with vital dye is longer than that
one using probe and that probe increases the costs. For
selected patients (inferior extremity cutaneous melanoma)
with superficial inguinal SN evidenced by preoperative
lymphoscintigraphy), PBD can securely be used alone,
improving the cost / benefit relationship of SNB procedure,
increasing the number of hospitals where it could be done.
Conclusion
Patent blue dye is enough to identify superficial
inguinal SN in cutaneous melanoma.
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